| Active, not recruiting | 2 | 72 | US | Dinaciclib, CDK Inhibitor SCH 727965, MK 7965, MK-7965, MK7965, SCH 727965, SCH-727965, SCH727965 | National Cancer Institute (NCI) | Acral Lentiginous Melanoma, Cutaneous Nodular Melanoma, Lentigo Maligna Melanoma, Low-CSD Melanoma, Mucosal Melanoma, Recurrent Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7 | 10/13 | 03/25 | | |
NCT04511013: A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases |
|
|
| Recruiting | 2 | 112 | US | Binimetinib, ARRY-162, ARRY-438162, MEK162, Mektovi, Encorafenib, Braftovi, LGX 818, LGX-818, LGX818, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo | SWOG Cancer Research Network, National Cancer Institute (NCI) | Acral Lentiginous Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Metastatic Mucosal Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8 | 06/27 | 06/27 | | |
| Active, not recruiting | 3 | 101 | US | Avelumab, Bavencio, MSB-0010718C, MSB0010718C, Peripheral Blood Collection, Placebo, placebo therapy, PLCB, normal saline solution | University of Washington, EMD Serono | Stage III Merkel Cell Carcinoma AJCC v8, Stage IIIB Merkel Cell Carcinoma AJCC v8, Stage IIIA Merkel Cell Carcinoma AJCC v8 | 04/26 | 02/29 | | |
